Christopher Cannon/LinkedIn
Feb 16, 2026, 13:21
Christopher Cannon: Factor XIa Inhibition Reduces Stroke by 26% Without Increasing Bleeding
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared a post on LinkedIn:
”Factor XIa inhibition works! When added to anti platelet therapy for ischemic stroke or TIA – it significantly reduced stroke by 26%, with no significant increase in bleeding!”
Title: Next-Generation Factor XIa Cuts Recurrent Stroke Risk by 26%— Asundexian prevented repeat strokes without bleeding side effects
Authors: Nicole Lou
Read the Full Article on MedPage Today։
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 16, 2026, 13:21Quamruz Zafar: Using the FAST Approach Saves Lives and Reduces Long Term Disability
-
Feb 16, 2026, 13:15Rishiraj Sinha: Strengthening Donor Ecosystems to Support Patient Blood Management
-
Feb 16, 2026, 13:13Tarek Dakakni: Mobile Stroke Units Make Treatment Faster, Clearer, and Smarter
-
Feb 16, 2026, 13:03Lamees Alsalehi: Presenting Age, Gender, and Comorbidity Patterns in Stroke at DINC 2026
-
Feb 16, 2026, 12:55Hussein Balfaqih: From Near‑Fatal Hemorrhage to Walking The Ward
-
Feb 16, 2026, 06:21C. Michael Gibson: Favorable Safety Outcomes With Asundexian
-
Feb 16, 2026, 06:18Jecko Thachil: What Do Clinicians Mean by “Coagulopathy”?
-
Feb 16, 2026, 06:04Inside 2026 Highlights of ASH in the Mediterranean, Middle East, and North Africa with Dr. Heghine Khachatryan
-
Feb 15, 2026, 10:56Don’t Miss PNH: Clinical Practice From ISTH – Medscape